N-Amino-anabasin | 86133-36-0

• 分子结构分类: 有机化合物 - 生物碱及其衍生物
• 英文名称: N-Amino-anabasin
• 英文别名: 2-(Pyridin-3-yl)piperidin-1-amine；2-pyridin-3-ylpiperidin-1-amine
• CAS: 86133-36-0
• 化学式: C₁₀H₁₅N₃
• 分子量: 177.249
• InChiKey: RBKLKVOOTGOALW-UHFFFAOYSA-N

物化性质

• 熔点：
  40-45 °C
• 沸点：
  146-147 °C(Press: 9 Torr)
• 密度：
  1.090±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (-)-棉子素 、 N-Amino-anabasin 以 乙醇 为溶剂， 以91%的产率得到5,5'-Diisopropyl-3,3'-dimethyl-8,8'-bis-{[(Z)-3,4,5,6-tetrahydro-2H-[2,3']bipyridinyl-1-ylimino]-methyl}-[2,2']binaphthalenyl-1,6,7,1',6',7'-hexaol
  参考文献：
  名称：

  Synthesis and antiviral activity of gossypol derivatives

  摘要：

  DOI：

  10.1007/bf00766687
• 作为产物：
  描述：

  N-亚硝基新烟草碱 在 锌 作用下， 以 溶剂黄146 为溶剂， 生成 N-Amino-anabasin
  参考文献：
  名称：

  Synthesis and antiviral activity of gossypol derivatives

  摘要：

  DOI：

  10.1007/bf00766687

文献信息

• Orechoff; Norkina, Chemische Berichte, 1932, vol. 65, p. 1126,1128
  作者：Orechoff、Norkina

  DOI：——

  日期：——
• INOYATOVA, D. A.;OTROSHCHENKO, O. S., SINTEZ. I REAKTSION. SPOSOBNOST ORGAN. SOEDIN., TASHKENT, 1983, 57-61
  作者：INOYATOVA, D. A.、OTROSHCHENKO, O. S.

  DOI：——

  日期：——
• [EN] PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] COMPOSÉS DE PICOLINAMIDE ET DE PYRIMIDINE-4-CARBOXAMIDE, LEUR PROCÉDÉ DE PRÉPARATION ET COMPOSITION PHARMACEUTIQUE LES COMPRENANT
  申请人：SK CHEMICALS CO LTD

  公开号：WO2011139107A2

  公开（公告）日：2011-11-10

  Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11β-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11β-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human- derived 11β-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LAD A), insulin tolerance syndromes, obesity, impaired glucose tolerane (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.